NovaBridge Biosciences (NBP) Return on Sales (2023)

NovaBridge Biosciences (NBP) reported Return on Sales of 0.3% for Q4 2023, up 62.52% quarter-over-quarter from 0.79% in Q3 2023.

NovaBridge Biosciences (NBP) Return on Sales (2023) Analysis & Trends

NovaBridge Biosciences (NBP) has 1 years of Return on Sales data on file, last reported at 0.3% in Q4 2023.

  • Return on Sales for Q4 2023 came in at 0.3%, changed N/A year-over-year; the trailing twelve-month figure through Dec 2023 was 0.3% (changed N/A YoY), and the FY2023 annual result was 1.99%, down 50.0% from the prior year.
  • Return on Sales climbed to 0.3% in Q4 2023 per NBP's latest filing, from 0.79% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.3% in Q4 2023 and troughed at 2.13% in Q2 2023.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) ROS (Qtr)
1 Alterity Therapeutics 814,307.08 Bn 814,307.05 Bn - -
2 Belite Bio 55,320.00 Bn 55,320.00 Bn - -
3 Quantum Biopharma 17,149.72 Bn 17,149.72 Bn - -
4 Legend Biotech 3,590.00 Bn 3,589.71 Bn 242.10 Mn 0.00%
5 Akari Therapeutics 1,650.72 Bn 1,650.72 Bn - -
6 Evaxion A 1,522.09 Bn 1,522.07 Bn - 0.00%
7 Psyence Biomedical 229.39 Bn 229.38 Bn - -
8 Vertex Pharmaceuticals 113.09 Bn 105.85 Bn 2.59 Bn 0.00%
9 Abivax 90.15 Bn 90.15 Bn - -
10 NovaBridge Biosciences 328.19 Mn 117.34 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2023 -0.30%
Sep 30, 2023 -0.79%
Jun 30, 2023 -2.13%